Skip to main content

Advertisement

SpringerLink
Log in

Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection

  • Review Article
  • Published:
Hepatology International Aims and scope Submit manuscript

Abstract

Introduction

Resistance in nucleoside/nucleotide analog (NA) therapy has always been a challenge in the management of chronic hepatitis B (CHB).

Clinical studies

Initially developed for the treatment of HIV infection, early in vitro and clinical observational studies had shown tenofovir disoproxil fumarate (TDF) to be also active against CHB. Recent data from various multicenter phase 3 and 4 clinical trials have confirmed TDF being able to achieve a high viral suppression in both NA-naive and -experienced CHB patients. There are also emerging data on the efficacy of TDF in decompensated CHB. Although there are in vitro studies identifying certain mutation loci associated with a reduced susceptibility to TDF, there have so far been no reports of virologic resistance to TDF in clinical studies. TDF has a favorable safety profile, although more long-term data would be needed.

Conclusions

TDF has the makings of an “ideal” first-line drug for the treatment of CHB.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med 2007;147:58–61

    Article  Google Scholar 

  2. World Health Organization. WHO Fact Sheet N*204. Published August 2008. [cited 2011 February]. http://www.who.int/mediacentre/factsheets/fs204/en/

  3. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61–68.

    Article  CAS  Google Scholar 

  4. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800–807

    Article  CAS  Google Scholar 

  5. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011–1020

    Article  CAS  Google Scholar 

  6. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576–2588

    Article  CAS  Google Scholar 

  7. Yuen MF, Lai CL. Treatment of chronic hepatitis B: evolution over two decades. J Gastroenterol Hepatol 2011;26:138–143

    Article  Google Scholar 

  8. Lai CL, Yuen MF. Chronic hepatitis B—new goals, new treatment. N Engl J Med 2008;359:2488–2491

    Article  CAS  Google Scholar 

  9. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886–893

    Article  CAS  Google Scholar 

  10. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521–1531

    Article  CAS  Google Scholar 

  11. Yuen MF, Seto WK, Chow DH, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007;12:1295–1303

    CAS  PubMed  Google Scholar 

  12. Yuen MF, Fung J, Wong DK, Lai CL. Prevention and management of drug resistance for antihepatitis B treatment. Lancet Infect Dis 2009;9:256–264

    Article  CAS  Google Scholar 

  13. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004;19:1276–1282

    Article  CAS  Google Scholar 

  14. Seto WK, Lai CL, Fung J, et al. Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. J Hepatol 2010

  15. Yang H, Westland CE, Delaney WEt, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002;36:464–473

    Article  CAS  Google Scholar 

  16. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006;44:283–290

    Article  CAS  Google Scholar 

  17. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503–1514

    Article  CAS  Google Scholar 

  18. Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422–430

    Article  CAS  Google Scholar 

  19. Reijnders JGP, Deterding K, Petersen J, et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol 2010;52:493–500

    Article  CAS  Google Scholar 

  20. Gallant JE, Deresinski S. Tenofovir disoproxil fumarate. Clin Infect Dis 2003;37:944–950

    Article  CAS  Google Scholar 

  21. De Clercq E, Holy A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discov 2005;4:928–940.

    Article  Google Scholar 

  22. Ying C, De Clercq E, Nicholson W, Furman P, Neyts J. Inhibition of the replication of the DNA polymerase M550 V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepatitis 2000;7:161–165

    Article  CAS  Google Scholar 

  23. van Bommel F, Wunsche T, Schurmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 2002;36:507–508

    Article  Google Scholar 

  24. Ristig MB, Crippin J, Aberg JA, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis 2002;186:1844–1847

    Article  CAS  Google Scholar 

  25. Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003;348:177–178

    Article  CAS  Google Scholar 

  26. Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004;189:1185–1192

    Article  CAS  Google Scholar 

  27. Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004;2:266–272

    Article  CAS  Google Scholar 

  28. Neff GW, Nery J, Lau DT, et al. Tenofovir therapy for lamivudine resistance following liver transplantation. Ann Pharmacother 2004;38:1999–2004

    Article  CAS  Google Scholar 

  29. Peters MG, Hann Hw H, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91–101

    Article  CAS  Google Scholar 

  30. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007;133:1445–1451

    Article  CAS  Google Scholar 

  31. Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006;43:1385–1391

    Article  CAS  Google Scholar 

  32. van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004;40:1421–1425

    Article  Google Scholar 

  33. van Bommel F, Zollner B, Sarrazin C, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006;44:318–325

    Article  Google Scholar 

  34. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442–2455

    Article  CAS  Google Scholar 

  35. Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132–143

    Article  CAS  Google Scholar 

  36. Heathcote EJ, Gane EJ, deMan RA, et al. Long term (4 year) efficacy and safety of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-positive patients (HBeAg+) with chronic hepatitis B (study 103): preliminary analysis (abstract). Hepatology 2010;52:556A

    Google Scholar 

  37. Marcellin P, Buti M, Krastev Z, et al. Continued efficacy and safety through 4 years of tenofovir disoproxil fumurate (TDF) treatment in HBeAg-negative patients with chronic hepatitis B (study 102): preliminary analysis (abstract). Hepatology 2010;52:555A

    Google Scholar 

  38. Gordon SC, Marcellin P, Krastev Z, et al. Four-year efficacy of tenofovir disoproxil fumarate (TDF) in chronic hepatitis B patients with high viral load (HBV DNA ≥ 9log copies/mL): preliminary analysis (abstract). Hepatology 2010;524:388A

    Google Scholar 

  39. Gane E, Lee SS, Heathcote EJ, et al. Efficacy/safety of tenofovir disoproxil fumarate (TDF) in Asians with HBeAg-positive/HBeAg-negative chronic hepatitis B (CHB), four year preliminary analysis (abstract). Hepatol Int 2011;5:11

    Google Scholar 

  40. Berg T, Marcellin P, Zoulim F, et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 2010;139:1207–1217

    Article  CAS  Google Scholar 

  41. Manns M, Berg T, Moller B, et al. Week 168 tenofovir DF (TDF) versus emtricitabine and TDF in viremic patients receiving adefovir dipivoxil for chronic hepatitis B (CHB) (abstract). Hepatol Int 2011;5:11

    Google Scholar 

  42. Patterson SJ, George J, Strasser SI, et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 2011;60:247–254

    Article  CAS  Google Scholar 

  43. Levrero M, Cimino L, Lampertico P, et al. Tenofovir (TDF) for chronic hepatitis B patients with suboptimal response to adefovir or adefovir/lamivudine treatment: results of the OPTIB Italian multicenter prospective open labal study (abstract). Hepatology 2010;52:389A

    Google Scholar 

  44. van Bommel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010;51:73–80

    Article  Google Scholar 

  45. Sablon E, Shapiro F. Advances in molecular diagnosis of HBV infection and drug resistance. Int J Med Sci 2005;2:8–16

    Article  CAS  Google Scholar 

  46. Niesters HG, Zoulim F, Pichoud C, et al. Validation of the INNO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment. Antimicrob Agents Chemother 2010;54:1283–1289

    Article  CAS  Google Scholar 

  47. Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207–210

    Article  CAS  Google Scholar 

  48. Fontana RJ, Keeffe EB, Carey W, et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002;8:433–439

    Article  Google Scholar 

  49. Chien RN, Lin CH, Liaw YF. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol 2003;38:322–327

    Article  CAS  Google Scholar 

  50. Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007;13:349–360

    Article  Google Scholar 

  51. Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010;52:176–182

    Article  CAS  Google Scholar 

  52. Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62–72

    Article  CAS  Google Scholar 

  53. Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009;50:2001–2006

    Article  CAS  Google Scholar 

  54. Wong VW, Wong GL, Yiu KK, et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol 2011;54:236–242

    Article  CAS  Google Scholar 

  55. Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 2011;53:774–780

    Article  CAS  Google Scholar 

  56. Daude M, Rostaing L, Saune K, et al. Tenofovir therapy in hepatitis B virus-positive solid-organ transplant recipients. Transplantation 2011;91:916–920.

    Article  CAS  Google Scholar 

  57. Jiménez-Pérez M, Sáez-Gómez AB, Mongil Poce L, Lozano-Rey JM, de la Cruz-Lombardo J, Rodrigo-López JM. Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant. Transplan Proc 2010;42:3167–3168

    Article  Google Scholar 

  58. Snow-Lampart A, Chappell B, Curtis M, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2010

  59. Sheldon J, Camino N, Rodes B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005;10:727–734

    CAS  PubMed  Google Scholar 

  60. WEt Delaney, Ray AS, Yang H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006;50:2471–2477

    Article  Google Scholar 

  61. Amini-Bavil-Olyaee S, Herbers U, Sheldon J, Luedde T, Trautwein C, Tacke F. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology 2009;49:1158–1165

    Article  CAS  Google Scholar 

  62. Fung S, Mazzuli T, Sherman M, Popovic V. Tenofovir (TDF) is effective in lamivudine (LAM)-resistant chronic hepatitis B patients who harbor rtA194T at baseline (abstract). Hepatology 2009;50:493A

    Google Scholar 

  63. Qi X, Xiong S, Yang H, Miller M, Delaney WEt. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007;12:355–362

    CAS  PubMed  Google Scholar 

  64. Villet S, Pichoud C, Billioud G, et al. Impact of hepatitis B virus rtA181 V/T mutants on hepatitis B treatment failure. J Hepatol 2008;48:747–755

    Article  CAS  Google Scholar 

  65. Dakin H, Bentley A, Dusheiko G. Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Value Health 2010;13:922–933

    Article  Google Scholar 

  66. Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010;139:1218–1229.e5

    Article  CAS  Google Scholar 

  67. Lui YY, Tsoi KK, Wong VW, et al. Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. Antivir Ther 2010;15:145–155

    Article  CAS  Google Scholar 

  68. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009;23:689–696

    Article  CAS  Google Scholar 

  69. Kohler JJ, Hosseini SH, Hoying-Brandt A, et al. Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest 2009;89:513–519

    Article  CAS  Google Scholar 

  70. Lebrecht D, Venhoff AC, Kirschner J, Wiech T, Venhoff N, Walker UA. Mitochondrial tubulopathy in tenofovir disoproxil fumarate-treated rats. J Acquir Immune Defic Syndr 2009;51:258–263

    Article  CAS  Google Scholar 

  71. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004;292:191–201

    Article  CAS  Google Scholar 

  72. Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005;20:743–746

    Article  CAS  Google Scholar 

  73. Buchacz K, Brooks JT, Tong T, et al. Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy. HIV Med 2006;7:451–456.

    Article  CAS  Google Scholar 

  74. Rifkin BS, Perazella MA. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med 2004;117:282–284

    Article  CAS  Google Scholar 

  75. Mathew G, Knaus SJ. Acquired Fanconi’s syndrome associated with tenofovir therapy. J Gen Intern Med 2006;21:C3–5

    Article  Google Scholar 

  76. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005;40:1194–1198

    Article  CAS  Google Scholar 

  77. de Vries-Sluijs TEMS, Reijnders JGP, Hansen BE, et al. Long-term therapy With tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology 2010;139:1934–1941

    Article  Google Scholar 

  78. Tan LK, Gilleece Y, Mandalia S, et al. Reduced glomerular filtration rate but sustained virologic response in HIV/hepatitis B co-infected individuals on long-term tenofovir. J Viral Hepat 2009;16:471–478

    Article  CAS  Google Scholar 

  79. Lampertico P, Vigano M, Yurdaydin C, et al. Effectiveness and safety of tenofovir disoproxil fumarate in field practice: a multicenter European cohort study of 737 patients with chronic hepatitis B (abstract). Hepatology 2010;52:503A

    Google Scholar 

  80. Grund B, Peng G, Gibert CL, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS 2009;23:1519–1529

    Article  CAS  Google Scholar 

  81. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009;49:S185–195

    Article  CAS  Google Scholar 

  82. Cassetti I, Etzel A, Madruga J, et al. The 10 year safety and efficacy of tenofovir disoproxil fumarate (TDF)-containing once-daily highly active antiretroviral therapy (HAART) (abstract). J Int AIDS Soc 2010;13:P86

    Article  Google Scholar 

  83. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 January 2010. Wilmington, NC: Registry Coordinating Center2010 [cited 2011 6 March]; http://www.apregistry.com/forms/interim_report.pdf

  84. Gilead Sciences. Full prescribing information for VIREAD tablets. 2010 [updated October 2010; cited March 2011]; http://www.gilead.com/pdf/viread_pi.pdf

  85. Liu J, Yang HI, Lee MH, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 2010;139:474–482

    Article  Google Scholar 

  86. Yuen MF, Wong DK, Sablon E, et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 2004;39:1694–1701

    Article  Google Scholar 

  87. Gish RG, Chang TT, Lai CL, et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat 2010;17:16–22

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong, Hong Kong

    Wai-Kay Seto, Man-Fung Yuen, James Fung & Ching-Lung Lai

Authors
  1. Wai-Kay Seto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Man-Fung Yuen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James Fung
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ching-Lung Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ching-Lung Lai.

Additional information

Serum HBV DNA levels are expressed as IU/mL in this review. If HBV DNA levels were originally quoted as copies/mL in their cited reference, they are converted from copies/mL to IU/mL in a ratio of 5.8:1.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seto, WK., Yuen, MF., Fung, J. et al. Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection. Hepatol Int 7, 327–334 (2013). https://doi.org/10.1007/s12072-011-9282-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-011-9282-y

Keywords

Search

Navigation